Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model

Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function

(2021) Courtney M. Williams et al.   FASEB JOURNAL

Geniposide suppresses liver injury in a mouse model of DDC ‐induced sclerosing cholangitis

(2021) Min Wen et al.   PHYTOTHERAPY RESEARCH

Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes

(2021) Jing-Yi Hu et al.   CHINESE MEDICAL JOURNAL

Intrahepatic cholestasis induced by α-naphthylisothiocyanate can cause gut-liver axis disorders

(2021) Zhengyuan Chen et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases

(2021) Claudio Pinto et al.   Cells

An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis

(2020) Yifeng Wang et al.   Nature Communications

FGF19 and FGF21 for the Treatment of NASH—Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human

(2020) Emma Henriksson et al.   Frontiers in Endocrinology

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma

(2019) Aroosha Raja et al.   Cells

The Biosynthesis, Signaling, and Neurological Functions of Bile Acids

(2019) Yoshimitsu Kiriyama et al.   Biomolecules

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma

(2019) Richard D Kim et al.   Cancer Discovery

Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial

(2018) Ibironke Oduyebo et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

NASH: Successful phase II trial of FGF19 analogue

(2018) Iain Dickson   Nature Reviews Gastroenterology & Hepatology

The gut–liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19

(2018) Marilidia Piglionica et al.   CURRENT OPINION IN PHARMACOLOGY

Developmental regulation of the gut-liver (FGF19-CYP7A1) axis in neonates

(2018) Naureen Memon et al.   Journal of Maternal-Fetal & Neonatal Medicine

Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis

(2018) Raffaella Maria Gadaleta et al.   Scientific Reports

New therapeutic concepts in bile acid transport and signaling for management of cholestasis

(2017) Michael Trauner et al.   HEPATOLOGY

RNA-binding protein ZFP36L1 maintains posttranscriptional regulation of bile acid metabolism

(2017) Elizabeth J. Tarling et al.   JOURNAL OF CLINICAL INVESTIGATION

Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization

(2017) Yang Liu et al.   STRUCTURE

Uncoupling the Mitogenic and Metabolic Functions of FGF1 by Tuning FGF1-FGF Receptor Dimer Stability

(2017) Zhifeng Huang et al.   Cell Reports

Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis

(2016) Supriya R. Kulkarni et al.   HEPATOLOGY

Bile Acids as Hormones: The FXR-FGF15/19 Pathway

(2015) Steven A. Kliewer et al.   DIGESTIVE DISEASES

Fibrates and cholestasis

(2015) Nisanne S. Ghonem et al.   HEPATOLOGY

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2 -deficient mice

(2015) Mei Zhou et al.   HEPATOLOGY

FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic–pituitary–adrenal axis

(2015) Rachel J. Perry et al.   Nature Communications

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19

(2014) M. Zhou et al.   CANCER RESEARCH

Activated AMPK explains hypolipidemic effects of sulfated low molecular weight guluronate on HepG2 cells

(2014) Xin Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A variant of FGF19 protects the liver from cholestatic injury without inducing cancer

(2014) Gillian Patman   Nature Reviews Gastroenterology & Hepatology

A nontumorigenic variant of FGF19 treats cholestatic liver diseases

(2014) J. Luo et al.   Science Translational Medicine

Pleiotropic Roles of Bile Acids in Metabolism

(2013) Thomas Q. de Aguiar Vallim et al.   Cell Metabolism

Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist

(2013) Sama I. Sayin et al.   Cell Metabolism

Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism

(2012) Hongfei Ge et al.   PLoS One

Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches

(2010) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1

(2010) Vassilis Triantis et al.   HEPATOLOGY

FGF15/FGFR4 Integrates Growth Factor Signaling with Hepatic Bile Acid Metabolism and Insulin Action

(2009) Dong-Ju Shin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bile acids: regulation of synthesis

(2009) John Y. L. Chiang   JOURNAL OF LIPID RESEARCH

Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice

(2009) X. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis

(2008) Frank G. Schaap et al.   HEPATOLOGY